Bupropion controlled-release - IntelGenx

Drug Profile

Bupropion controlled-release - IntelGenx

Alternative Names: Bupropion extended-release; CPI-300; Forfivo XL; INT 0004/2006

Latest Information Update: 06 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cary Pharmaceuticals; IntelGenx Corp.
  • Developer IntelGenx Corp.
  • Class Antidepressants; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Major depressive disorder

Highest Development Phases

  • Marketed Major depressive disorder

Most Recent Events

  • 02 Dec 2014 IntelGenx extends license agreement with Edgemont Pharmaceuticals for the commercialisation of bupropion controlled-release in USA
  • 27 Nov 2014 Bupropion controlled-release - IntelGenx is available for licensing in (excluding USA) as of 27 Nov 2014. http://www.intelgenx.com
  • 28 Aug 2013 Wockhardt Bio AG advises IntelGenx of an ANDA submission to manufacture and market generic versions of Fortivo® XL 450mg capsules in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top